{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:48:11Z","timestamp":1793656091966,"version":"4.5.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.euroneuro.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T13:26:52Z","timestamp":1664544412000},"page":"44-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-1041","authenticated-orcid":false,"given":"Chaomei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Daure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Buot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-1749","authenticated-orcid":false,"given":"Michael","family":"Ljuslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Verroust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8549-6599","authenticated-orcid":false,"given":"Yasser","family":"Khazaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Rothen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Thorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5771-5750","authenticated-orcid":false,"given":"Muhammad Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1580","authenticated-orcid":false,"given":"David","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-5596","authenticated-orcid":false,"given":"Michel","family":"Sab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.09.004_bib0001","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/npp.2016.186","article-title":"Ketamine treatment and global brain connectivity in major depression","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00223980.1955.9916156","article-title":"Lysergic Acid Diethylamide (LSD-25): I. Physiological and perceptual responses","volume":"39","author":"Abramson","year":"1955","journal-title":"J. Psychol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/2050324520974484","article-title":"2019: A year of expansion in psychedelic research, industry, and deregulation","volume":"6","author":"Aday","year":"2020","journal-title":"Drug Sci. Policy Law"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: An R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J. Informetr."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(17)31467-8","article-title":"Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial","volume":"390","author":"Avidan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0007","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/S2468-2667(21)00248-6","article-title":"Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study","volume":"7","author":"Barocas","year":"2022","journal-title":"Lancet. Public Heal."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0026-895X(25)10753-0","article-title":"Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors","volume":"12","author":"Bennett","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/AJP.0000000000000821","article-title":"Effect on opioids requirement of early administration of intranasal ketamine for acute traumatic pain","volume":"36","author":"Bouida","year":"2020","journal-title":"Clin. J. Pain"},{"issue":"24","key":"10.1016\/j.euroneuro.2022.09.004_bib0011","article-title":"Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis","volume":"4","author":"Brady","year":"2017","journal-title":"Inj. Epidemiol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0016","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nrl.2011.07.003","article-title":"Hallucinogenic drugs in pre-Columbian Mesoamerican cultures","volume":"30","author":"Carod-Artal","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0018","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1152\/ajplegacy.1901.5.3.158","article-title":"The physiological action of three poisonous toadstools\u2014Amanita Muscaria, Amanita Verna or Bulbosa, and Amanita Phalloides","volume":"5","author":"Carter","year":"1901","journal-title":"Am. J. Physiol. Content"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/asi.21694","article-title":"Predictive effects of structural variation on citation counts","volume":"63","author":"Chen","year":"2012","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0021","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1126\/science.155.3768.1417","article-title":"Chromosomal damage in human leukocytes induced by lysergic acid diethylamide","volume":"155","author":"Cohen","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","article-title":"Lysergic acid diethylamide: side effects and complications","volume":"130","author":"Cohen","year":"1960","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0024","series-title":"Allgemeine klinische erfahrungen mit ketamine bei mehr als 1500 fallen","first-page":"18","author":"Corssen","year":"1968"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"915","key":"10.1016\/j.euroneuro.2022.09.004_bib0026","article-title":"Knowledge and use of novel psychoactive substances in an italian sample with substance use disorders","volume":"19","author":"Dal Farra","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0028","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","author":"de la Fuente Revenga","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0006-8993(92)90661-R","article-title":"Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies","volume":"571","author":"Deecher","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0032","series-title":"Psychedelic Psychiatry: LSD from Clinic to Campus","author":"Dyck","year":"2008"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0033","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1503\/cmaj.109-4626","article-title":"Health minister ends special access to prescription heroin","volume":"185","author":"Eggertson","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11192-006-0144-7","article-title":"Theory and practise of the g-index","volume":"69","author":"Egghe","year":"2006","journal-title":"Scientometrics"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0035","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1227\/00006123-199512000-00007","article-title":"Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation","volume":"37","author":"Eide","year":"1995","journal-title":"Neurosurgery"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.707057","article-title":"Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy","volume":"12","author":"Eleftheriou","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0037","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.18632\/oncotarget.13743","article-title":"Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0038","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"650","key":"10.1016\/j.euroneuro.2022.09.004_bib0039","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euroneuro.2021.04.024","article-title":"The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study","volume":"49","author":"Feeney","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"43","key":"10.1016\/j.euroneuro.2022.09.004_bib0041","article-title":"Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models","volume":"14","author":"Foldi","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2307\/3033543","article-title":"A set of measures of centrality based on betweenness","volume":"40","author":"Freeman","year":"1977","journal-title":"Sociometry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0043","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/dta.3170","article-title":"Development and validation of a rapid LC-MS\/MS method for the detection of 182 novel psychoactive substances in whole blood","volume":"14","author":"Giorgetti","year":"2022","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0044","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"463","key":"10.1016\/j.euroneuro.2022.09.004_bib0045","article-title":"The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d)","volume":"55","author":"Green","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2680","article-title":"How citation distortions create unfounded authority: analysis of a citation network","volume":"339","author":"Greenberg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0047","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0048","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0049","unstructured":"H. Ey, Claude, H., 1934. La Mescaline, Substance Hallucinog\u00e8ne, Comptes-Rendus Des S\u00e9ances de La Soci\u00e9t\u00e9 de Biologie CXV."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0050","first-page":"1","article-title":"The psychedelic renaissance in clinical research: a bibliometric analysis of three decades of human studies with psychedelics","author":"Hadar","year":"2022","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0051","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-O","article-title":"Toxicity and deaths from 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d)","volume":"340","author":"Henry","year":"1992","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0052","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/15563650.2014.976792","article-title":"Current European data collection on emergency department presentations with acute recreational drug toxicity: Gaps and national variations","volume":"52","author":"Heyerdahl","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0053","unstructured":"Hofmann, A., 1980. LSD, My Problem Child. New York."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0054","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0057","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0058","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2468-2667(19)30128-8","article-title":"Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study","volume":"4","author":"Kalkman","year":"2019","journal-title":"Lancet Public Heal."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0059","first-page":"1","article-title":"The psychedelic renaissance: the next trip for psychiatry?","author":"Kelly","year":"2019","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000487590","article-title":"Global scientific production on illicit drug addiction: a two-decade analysis","volume":"24","author":"Khalili","year":"2018","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0061","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a hallucinogen-activated Gq-coupled 5-HT(2A) serotonin receptor","volume":"182","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0062","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1024940629314","article-title":"Bursty and hierarchical structure in streams","volume":"7","author":"Kleinberg","year":"2003","journal-title":"Data Min. Knowl. Discov."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0063","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00204-022-03224-2","article-title":"Developments in high-resolution mass spectrometric analyses of new psychoactive substances","volume":"96","author":"Klingberg","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0064","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/02791072.2021.1874573","article-title":"Trends in the top-cited articles on classic psychedelics","volume":"53","author":"Lawrence","year":"2021","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109838","article-title":"Simultaneous EEG\/fMRI recorded during ketamine infusion in patients with major depressive disorder","volume":"99","author":"McMillan","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0067","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0068","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0069","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0071","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0072","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"37","key":"10.1016\/j.euroneuro.2022.09.004_bib0073","article-title":"Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy","volume":"17","author":"Mocanu","year":"2022","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0074","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0075","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0076","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0077","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0078","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0079","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tree.2018.11.007","article-title":"Research weaving: visualizing the future of research synthesis","volume":"34","author":"Nakagawa","year":"2019","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0081","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0082","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b13,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0083","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217951","article-title":"Candidate strategies for development of a rapid-acting antidepressant class that does not result in neuropsychiatric adverse effects: prevention of ketamine-induced neuropsychiatric adverse reactions","volume":"21","author":"Okada","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0084","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","article-title":"NMDA antagonist neurotoxicity: mechanism and prevention","volume":"254","author":"Olney","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0085","series-title":"The Trials of Psychedelic Therapy: Lsd Psychotherapy in America","author":"Oram","year":"2018"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0086","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0017816000027577","article-title":"The psychedelic mystical experience in the human encounter with death","volume":"62","author":"Pahnke","year":"1969","journal-title":"Harv. Theol. Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0088","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/YCO.0000000000000607","article-title":"Drug checking to detect fentanyl and new psychoactive substances","volume":"33","author":"Palamar","year":"2020","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0089","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0090","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0091","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1542\/peds.99.3.427","article-title":"Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children","volume":"99","author":"Parker","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0092","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/1742-6723.13752","article-title":"Establishing the protocols for the South Australian Emergency Department Admission Blood Psychoactive Testing (EDABPT) programme for drug surveillance","volume":"33","author":"Partridge","year":"2021","journal-title":"Emerg. Med. Australas"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0093","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0094","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The toxicology of bath salts: a review of synthetic cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0095","article-title":"Les Champignons Hallucinog\u00e8nes Du Mexique\u00a0: \u00c9tudes Ethnologiques, Taxinomiques, Biologiques, Physiologiques et Chimiques","volume":"7","author":"R Heim","year":"1958","journal-title":"Arch. Du Mus\u00e9um Natl. d'histoire Nat."},{"issue":"142","key":"10.1016\/j.euroneuro.2022.09.004_bib0096","article-title":"Exploring the baseline knowledge and experience of healthcare professionals in the United Kingdom on novel psychoactive substances","volume":"10","author":"Ramos","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0097","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0098","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104608","article-title":"Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends","volume":"136","author":"Sabe","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0033291719001727","article-title":"New\/emerging psychoactive substances and associated psychopathological consequences","volume":"51","author":"Schifano","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0101","series-title":"The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society","author":"Sessa","year":"2012"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0102","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/asi.20994","article-title":"Comparative study on methods of detecting research fronts using different types of citation","volume":"60","author":"Shibata","year":"2009","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(19)30533-4","article-title":"Approval of esketamine for treatment-resistant depression","author":"Singh","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/asi.4630240406","article-title":"Co-citation in the scientific literature: a new measure of the relationship between two documents","volume":"24","author":"Small","year":"1973","journal-title":"J. Am. Soc. Inf. Sci."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1742-6723.13839","article-title":"The Emerging Drugs Network of Australia: a toxicosurveillance system of illicit and emerging drugs in the emergency department","volume":"34","author":"Smith","year":"2022","journal-title":"Emerg. Med. Australas"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.158.3801.669","article-title":"2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug","volume":"158","author":"Snyder","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0110","doi-asserted-by":"crossref","DOI":"10.1111\/acps.12556","article-title":"Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis","volume":"133","author":"Solmi","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.psyneuen.2014.09.031","article-title":"Inflammatory cytokines and anorexia nervosa: a meta-analysis of cross-sectional and longitudinal studies","volume":"51","author":"Solmi","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0112","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/add.13457","article-title":"The association between smoking prevalence and eating disorders: a systematic review and meta-analysis","volume":"111","author":"Solmi","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(20)30566-6","article-title":"Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis","volume":"8","author":"Solmi","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.chc.2008.07.013","article-title":"Outcome of eating disorders","author":"Steinhausen","year":"2009","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"#cr-split#-10.1016\/j.euroneuro.2022.09.004_bib0115.1","unstructured":"Therapsil, 2020. 4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1)\u00a0"},{"key":"#cr-split#-10.1016\/j.euroneuro.2022.09.004_bib0115.2","unstructured":"first legal medical exemptions for psilocybin in Canada since 1970's [WWW Document]. URL https:\/\/therapsil.ca\/4-palliative-canadians-approved-for-end-of-life-psilocybin-therapy-through-section-561-first-legal-medical-exemptions-for-psilocybin-in-canada-since-1970s\/"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0116","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0117","unstructured":"USA Congress, 1962. Act of October 10, 1962 (Drug Amendments Act of 1962), Enrolled A. ed."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1162\/qss_a_00112","article-title":"Large-scale comparison of bibliographic data sources: Scopus, Web of Science, Dimensions, Crossref, and Microsoft Academic","volume":"2","author":"Visser","year":"2021","journal-title":"Quant. Sci. Stud."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)33152-5","article-title":"Substance use among young people in China: a systematic review and meta-analysis","volume":"390","author":"Wang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0120","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.890840","article-title":"Trends in mortality from novel psychoactive substances as \u201clegal highs\u201d: gender differences in manner of death and implications for risk differences for women","volume":"13","author":"Webb","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000542-198202000-00007","article-title":"Ketamine\u2013its pharmacology and therapeutic uses","volume":"56","author":"White","year":"1982","journal-title":"Anesthesiology"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0122","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","article-title":"Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca","volume":"7","author":"Winkelman","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0004867419883341","article-title":"Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials","volume":"54","author":"Witt","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.09.004_bib0125","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front. psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0126","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0127","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0128","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","author":"Yao","year":"2021","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0129","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2022.09.004_bib0131","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1073\/pnas.76.10.5372","article-title":"Specific [3H]phencyclidine binding in rat central nervous system","volume":"76","author":"Zukin","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22008471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22008471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:04:30Z","timestamp":1760378670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22008471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":129,"alternative-id":["S0924977X22008471"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.09.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}